Delivery Order SPE2DB20D1004-SPE2DB22FF8J0

Award Date 6/27/22
Potential Completion Date 6/28/22
Potential Value $1.1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $11,648.39, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product, with a completion date of October 21, 2024. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at...
This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $3,983.27 firm-fixed-price delivery order contract is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical division. This IDC serves as a primary vehicle for providing a...
This federal contract award, issued by the Defense Logistics Agency (DLA), was granted to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $51,368.19, is for the delivery of RESTASIS 0.05% Eye Emulsion 60s, a prescription eye medication. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award, valued at $3,080.28, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The contract is a firm fixed-price Delivery Order, with an ultimate completion date of October 17, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of RESTASIS 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, and has a ceiling value of $7,266.33. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA valued at $999,999,999, which serves as a primary vehicle for...
This federal contract award is for a delivery order placed by the Defense Logistics Agency (DLA) with Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,843.23 firm fixed-price contract is for the delivery of RESTASIS 0.05% eye emulsion, a specialty medication used to treat dry eye disease. The contract award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $6,496.68 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product. The award is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC...
This federal contract award, valued at $1,080.48, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RESTASIS 0.05% eye emulsion. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary vehicle for Amerisourcebergen to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $1,080.48, is for the delivery of RESTASIS 0.05% eye emulsion medication. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical division, valued at up to $999,999,999.00 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,558,152,346 units of RESTASIS 0.05% eye emulsion. The $8,122.89 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 held by Amerisourcebergen's parent company, Cencora, Inc., which runs through November 2026. This IDC serves as the primary vehicle for Cencora,...
  • SPE2DB20D1004
    Indefinite Delivery Contract
  • SPE2DB20D1004-SPE2DB22FF8J0
    Delivery Order

The federal contract award summarized in the provided information was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,087.58, is for the delivery of RESTASIS 0.05% eye emulsion, a specialty pharmaceutical product.

This contract award appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 2/27/25, 12:13 PM